DUBLIN–(BUSINESS WIRE)–The “Antibiotics Market Size, Share & Trends Analysis Report 2023-2030” report has been added to ResearchAndMarkets.com’s offering.
The global antibiotics market size is expected to reach USD 68.04 billion by 2030, registering a CAGR of 4.26% from 2023 to 2030, according to this report.
High demand, increasing focus on antibiotic resistance programs, initiatives undertaken to avoid the misuse of antibiotics, and easy availability of generic drugs are responsible for market growth. The purchasing process of antibiotics is primarily influenced by physicians.
The availability of multiple generic products provides buyers with easy switching options. In the case of institutional businesses, price discounts play an important role in the selection procedure. This can further reduce the profit margins of market players. However, buyers do not have these privileges in branded or patented products.
Furthermore, regulatory authorities have issued the guidelines for limited use of fluoroquinolones. Hence, the bargaining power of buyers is anticipated to be low over the forecast period. According to the State of World’s Antibiotics report, in 2021, the overall antimicrobial drug usage in India has increased sharply by 30%.
Moreover, according to the CDC’s Antibiotics Usage in United States report, 2021 update, around 25 million prescriptions were dispensed from U.S. retail pharmacies. Among them, azithromycin was the leading formulation prescribed in 2021. Thus, the rising consumption pattern of antibacterial drugs is likely to fuel the market growth during the projected period. New product approvals and launches are expected to support market growth.
Companies Mentioned
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Viatris, Inc
- Melinta Therapeutics LLC
- Cipla, Inc
- Shionogi & Co., Ltd
- KYORIN Pharmaceutical Co., Ltd
- GSK plc
- AbbVie, Inc.
- Lupin Pharmaceuticals, Inc.
Antibiotics Market Report Highlights
- Owing to the dearth of commercial success of newly developed antibiotics, government & non-government bodies implemented certain strategies to incentivize antibacterial drug R&D activities
- For instance, the government alliance with BARDA is supporting various companies to facilitate R&D activities in novel therapies for infectious diseases. BARDA has been associated with several pharmaceutical companies like AstraZeneca and GSK plc
- The cell wall synthesis inhibitor segment held the largest share in 2022 owing to its wide spectrum of activity against gram-positive and gram-negative bacteria
- The RNA synthesis inhibitors segment is anticipated to register the fastest CAGR from 2023 to 2030 due to a surge in product launches and R&D initiatives
- The generic type segment held the largest share in 2022 due to the affordability of generic formulations and government initiatives to adopt generic drugs
- The penicillin drug class segment led the market in 2022. However, the cephalosporin segment is anticipated to register the fastest CAGR from 2023 to 2030
- Asia Pacific is expected to exhibit the fastest CAGR over the forecast period due to the rising investments by leading players and the high adoption of generic antibiotics in the region
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2022 – 2030 |
| Estimated Market Value (USD) in 2022 | $48.73 Billion |
| Forecasted Market Value (USD) by 2030 | $68.04 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Antibiotics Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Development of advanced products
3.2.1.2 Increasing prevalence of infectious diseases
3.2.1.3 Growing collaborations for development of antibiotics
3.2.2 Market restraint analysis
3.2.2.1 High number of patent expirations
3.2.2.2 High R&D cost
3.3 Penetration & Growth Prospect Mapping
3.4 Antibiotics: Market Analysis Tools
3.4.1 Industry analysis – Porter’s
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
Chapter 4 Antibiotics Market Segment Analysis, By Type, 2018-2030 (USD Million)
Chapter 5 Antibiotics Market Segment Analysis, By Action Mechanism 2018-2030 (USD Million)
Chapter 6 Antibiotics Market Segment Analysis, By Drug Class, 2018-2030 (USD Million)
Chapter 7 Antibiotics Market Segment Analysis, By Region, 2018 – 2030 (USD Million)
Chapter 8 Antibiotics Market – Competitive Analysis
For more information about this report visit https://www.researchandmarkets.com/r/mv9uh0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900